Belimumab: Review of Use in Systemic Lupus Erythematosus

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1006-1022

  Boyce, Eric G ^a   Fusco, Bryan E ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Belimumab; Pharmacotherapy; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; LIVE VACCINE; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS;

ANTIGEN ANTIBODY COMPLEX; AREA UNDER THE CURVE; ARTHRALGIA; CLINICAL RESEARCH; CLINICAL TRIAL; COCHRANE LIBRARY; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INFORMATION; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPOTENSION; INFLAMMATION; INFLUENZA; INJECTION SITE REACTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDLINE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PEER REVIEW; PERICARDITIS; PLEURISY; PRACTICE GUIDELINE; REVIEW; RHINOPHARYNGITIS; SCORING SYSTEM; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG INTERACTIONS; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 84860191332     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.028     Document Type: Review

References (39)

1. Belimumab [package insert] Human Genome Sciences, Inc. and GlaxoSmithKline, Accessed November 7, 2011. http://www.hgsi.com/images/Benlysta/pdf/benlysta_pi.pdf.
2. Benlysta Product Monograph GlaxoSmithKline, Accessed November 7, 2011. http://www.gsk.ca/english/docs-pdf/product-monographs/Benlysta.pdf.
3. FDA approves Benlysta to treat lupus US Food and Drug Administration, Accessed October 16, 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm.
4. CHMP backs Benlysta Zacks Investment Research, Accessed October 28, 2011. http://www.zacks.com/stock/news/53802/CHMP+Backs+Benlysta.
5. Summary Basis of Decision (SBD) for BENLYSTA Health Canada, Accessed January 26, 2012. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2011_benlysta_137699-eng.php.
6. Rahman A., Isenberg D.A. Systemic lupus erythematosus: mechanism of disease. N Engl J Med 2008, 358:929-939.
7. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277.
8. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40:1725. Letter.
9. Bertsias G.K., Ioannidis J.P.A., Boletis J., et al. EULAR recommendations for the management of systemic lupus erythematosus (SLE): report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2009, 68:477-483.
10. Guidance for industry: systemic lupus erythematosus-developing medical products for treatment US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, Accessed November 7, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf.
11. Lee S., Ballow M. Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. J Allergy Clin Immunol 2010, 125:814-820.
12. Baker K.P., Edwards B.M., Main S.H., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
13. Petri M., Stohl W., Chatham W., et al. Association of plasma B-lymphocyte stimulator (BLyS) levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58:2453-2459.
14. Furie R.A., Petri M.A., Wallace D.J., et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61:1143-1151.
15. Hay E.M., Bacon P.A., Gordon C., et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993, 86:447-458.
16. Petri M., Kim M.Y., Kalunian K.C., et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005, 353:2550-2558. OC-SELENA Trial.
17. Isenberg D.A., Allen E., Farewell V., et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011, 70:54-59.
18. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options: part I. J Am Acad Dermatol 2011, 65:e179-e193.
19. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: Update of therapeutic options: part II. J Am Acad Dermatol 2011, 65:e195-e213.
20. Lander S.A., Wallace D.J., Weisman M.H. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus 2002, 11:340-347.
21. Horizon A.A., Wallace D.J. Risk: benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf 2004, 3:273-278.
22. Man B.L., Mok C.C. Serositis related to systemic lupus erythematosus: prevalence and outcome. Lupus 2005, 14:822-826.
23. Pauzner R., Dulitzki M., Langevitz P., et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost 2001, 86:1379-1384.
24. Crowther M.A., Ginsberg J.S., Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138.
25. Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:620-625.
26. Tokunga M., Saito K., Kawabata D., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475.
27. Ginzler E.M., Dooley M.A., Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228.
28. Gunnarsson I., Sundelin B., Jónsdóttir T., et al. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthr Rheum 2007, 56:1263-1272.
29. Halpern W.G., Lappin P., Zanardi T., et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci 2006, 91:586-599.
30. Jacobi A.M., Huang W., Wang T. The effect of prolonged treatment with belimumab on B cells in human SLE. Arthritis Rheum 2010, 62:201-210.
31. Furie R., Stohl W., Ginzler E.M., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109.
32. Auyeung-Kima D.J., Devalarajab M.N., Migoneb T.S., et al. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reproductive Toxicol 2009, 28:443-455.
33. Wallace D.J., Stohl W., Furie R.A., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178.
34. Navarra S.V., Guzmán R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
35. Furie R., Petri M., Zamani O., et al. A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits BLyS, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
36. Code of Federal Regulations Title 21, Part 201, Subpart B, Sec. 201.57, (c) (9) (i) 8.1 Pregnancy Food and Drug Administration, Accessed November 7, 2011. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=201.57.
37. Hotline: belimumab for systemic lupus erythematosus American College of Rheumatology, Accessed November 2, 2011. http://www.rheumatology.org/publications/hotline/2011_03_15_belimumab.asp.
38. Slawsky K.A., Fernandes A.W., Fusfeld L., et al. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res 2011, 63:1224-1232.
39. Zhu T.Y., Tam L.S., Li E.K. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res 2011, 63:751-760.